Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/37009
Title: | Association of Disease Subtype and Duration with Echocardiographic Evidence of Pulmonary Hypertension in Myeloproliferative Neoplasm | Authors: | Yaylalı, Yalın Tolga Yılmaz, Samet Akgün-Cağlıyan, Gülsüm Kılıç, Oğuz Kaya, E. Senol, H. Özen, Furkan |
Keywords: | hemoglobin uric acid adult Article cancer diagnosis computer assisted tomography controlled study correlational study disease association disease duration female follow up human lung artery pressure major clinical study male middle aged myelofibrosis myeloproliferative neoplasm pulmonary hypertension pulmonologist retrospective study transthoracic echocardiography tricuspid regurgitation velocity |
Publisher: | S. Karger AG | Abstract: | Background: Pulmonary hypertension (PH) can complicate the course of myeloproliferative neoplasms (MPNs). Echocardiography is a useful noninvasive screening test for PH in populations at risk. We aimed to investigate the echocardiographic evidence of PH and clinical characteristics of patients with MPNs. Methods: This study included 197 patients with MPNs (mean age, 59 ± 14 years; females, 53%; mean disease duration, 3.4 ± 2.8 years). Clinical and laboratory characteristics, including JAK2V617F mutation status, were obtained. All participants underwent a comprehensive transthoracic echocardiographic examination. The echocardiographic evidence of PH was defined as systolic pulmonary artery pressure (SPAP) ?40 mm Hg. Results: Overall, 11 patients (5.5%) with SPAP ?40 mm Hg had echocardiographic evidence of PH. Patients with myelofibrosis had echocardiographic evidence of PH more often than patients with other MPNs (p < 0.001). Disease duration since the diagnosis of MPNs was 6.7 ± 4.6 years in the PH group and 3.1 ± 2.5 years in the non-PH group (p < 0.001). There was a weak positive correlation between SPAP values and time since diagnosis (r = 0.236, p =0.001). JAK2V617F mutation was not associated with PH. In multivariate logistic regression analysis, the presence of myelofibrosis (odds ratio [OR]: 22.177, 95% CI: 4.480-109.790, p < 0.001), long disease duration (OR: 1.217, 95% CI: 1.024-1.447, p = 0.026), and high uric acid levels (OR: 1.868, 95% CI: 1.049-3.328, p = 0.034) were found to be related with the echocardiographic evidence of PH. Survival was worse in the PH group (p = 0.0001). Conclusion: Our results suggest that patients with myelofibrosis are more likely to develop PH than other MPNs patients. Disease duration may predict the development of PH in MPN patients. © 2020 S. Karger AG. All rights reserved. | URI: | https://hdl.handle.net/11499/37009 https://doi.org/10.1159/000506596 |
ISSN: | 1011-7571 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
506596.pdf | 394.81 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
3
checked on Aug 17, 2024
WEB OF SCIENCETM
Citations
2
checked on Jul 31, 2024
Page view(s)
62
checked on Aug 24, 2024
Download(s)
24
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.